Truist downgraded Biomea Fusion from Buy to Hold
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/13/2026 | $8.00 | Buy | Rodman & Renshaw |
| 8/28/2025 | $5.00 | Buy | Jefferies |
| 6/3/2025 | $7.00 | Overweight | Piper Sandler |
| 10/9/2024 | $128.00 | Buy | Edward Jones |
| 9/27/2024 | $18.00 | Neutral → Buy | Rodman & Renshaw |
| 9/27/2024 | $54.00 | Hold → Buy | Truist |
| 8/29/2024 | $25.00 | Overweight | CapitalOne |
| 6/11/2024 | Buy → Hold | Truist |
10-Q - Biomea Fusion, Inc. (0001840439) (Filer)
8-K - Biomea Fusion, Inc. (0001840439) (Filer)
8-K - Biomea Fusion, Inc. (0001840439) (Filer)
4 - Biomea Fusion, Inc. (0001840439) (Issuer)
4 - Biomea Fusion, Inc. (0001840439) (Issuer)
4 - Biomea Fusion, Inc. (0001840439) (Issuer)
•Translational data presented at ADA demonstrate icovamenib's potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes • Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced • Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist
Collaboration will Assess the Potential Impact of the Combination of Icovamenib and Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health and Metabolic OutcomesLate-Breaking Preclinical Findings at the American Diabetes Association Annual Meeting June 5-8 Highlighting Potential Mechanisms through which Icovamenib may Support Metabolic Health SAN CARLOS, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea," "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced a collaboration with the University of Leicester as part of the ongoing platform research study titled Investigating and Optimizing
SAN CARLOS, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced that management will participate in the following investor conferences: H.C. Wainwright 4th Annual BioConnect Investor Conference: Biomea will participate in a fireside chat from 3:00–3:30 PM ET and in one-on-one meetings on May 19, 2026, in New York, NY.2026 Jefferies Global Healthcare Conference: Biomea will participate in a fireside chat from 8:10–8:40 AM ET and in one-on-one meetings on June 4, 2026, in New York, NY. An audio webcast of the fireside chats will be available here or by visiting the News & Ev
4 - Biomea Fusion, Inc. (0001840439) (Issuer)
4 - Biomea Fusion, Inc. (0001840439) (Issuer)
5 - Biomea Fusion, Inc. (0001840439) (Issuer)
Rodman & Renshaw initiated coverage of Biomea Fusion with a rating of Buy and set a new price target of $8.00
Jefferies initiated coverage of Biomea Fusion with a rating of Buy and set a new price target of $5.00
Piper Sandler resumed coverage of Biomea Fusion with a rating of Overweight and set a new price target of $7.00
SAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea," "Biomea Fusion" or the "Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, today announced the appointment of Julianne Averill to its Board of Directors (the "Board"), effective July 22, 2025. Ms. Averill has also been appointed to serve as a member of the Audit Committee. She succeeds Bihua Chen, who has stepped down from the Board after more than four years of dedicated service. "Julianne is an accomplished leader whose extensive financial, operational, and strategic expertise in the life sciences and digital health industries will be a tremendous asset to Biomea. Her prov
Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway Icovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes patients and patients that are currently uncontrolled on a GLP-1 based therapyBiomea's next generation oral GLP-1 receptor agonist (BMF-650) filing for IND All other clinical and preclinical activities are either being partnered or closed REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the first quarter ended March 31, 202
Mick Hitchcock, Ph.D., appointed Interim Chief Executive OfficerBiomea preparing icovamenib for late-stage clinical developmentMultiple milestones anticipated in 2025 including:FDA meeting anticipated in first half 2025 to discuss icovamenib late-stage development in severe insulin deficient patientsCOVALENT-111 (T2D) 52-week data anticipated in second half 2025COVALENT-112 (T1D) open label data anticipated in second half 2025BMF-650 IND application submission planned in second half 2025 REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, reported
A 52% increase from baseline in mean C-peptide AUC at Week 12 in patients diagnosed within 0–3 years (n=5) receiving icovamenib 200 mg, with a clear dose response observed vs 100 mg (n=6)Persistence observed through Week 52, with mean C-peptide AUC largely preserved in 200 mg group (~7% decline from baseline) following only 12 weeks of dosingPreservation of C-peptide also observed in patients diagnosed between 3-15 years (n=9)Icovamenib was generally well tolerated across all dosing arms and demonstrated a favorable safety and tolerability profile through Week 52 Comprehensive dataset to be presented at the American Diabetes Association's (ADA) Scientific Sessions (abstract is preliminary un
Icovamenib showed a sustained treatment benefit at Week 52 (9 months past the end of treatment) in the severe insulin-deficient diabetes patient population taking one or more antihyperglycemic medications at baseline, with a 1.8% placebo adjusted mean reduction in HbA1c (Arm B)Type 2 diabetes patients on a GLP-1-based therapy failing to achieve their target HbA1c also showed a clinically meaningful response from only 12 weeks of icovamenib treatment with a mean placebo adjusted HbA1c reduction of 1.8% (Arms A, B, and C combined) at Week 52Icovamenib was generally well tolerated across all dosing arms and demonstrated a favorable safety and tolerability profile through Week 52 Phase II trials
Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient populationBest response achieved in target, beta-cell deficient patients on one or more antidiabetic agents at baseline, showing a placebo-adjusted mean reduction of 1.47% in HbA1c at Week 26 with statistical significance, after only 12 weeks of dosing icovamenib with 100 mgIcovamenib was well-tolerated, with no adverse-event related discontinuations, no hypoglycemic events and no serious adverse events REDWOOD CITY, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company
SC 13G/A - Biomea Fusion, Inc. (0001840439) (Subject)
SC 13G/A - Biomea Fusion, Inc. (0001840439) (Subject)
SC 13G - Biomea Fusion, Inc. (0001840439) (Subject)